French National Authority for Health (HAS) has issued additional clarifications about planned change of add-on reimbursement of peripheral vascular stents

04

Sep 2017

National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) has been working on amending peripheral vascular implant section of the add-on reimbursement (LPPR) list since 2015.

In March 2016, CNEDiMTS issued the report and opinion, in which the following four new generic categories of peripheral vascular stents were proposed:

  • Self-expanding endoprostheses;
  • Balloon expandable stents;
  • Self-expanding covered stents (stent-grafts);
  • Balloon-expandable covered stents (stent-grafts).

CNEDiMTS confirmed that it did not observe any added benefits of one generic category of stents over the others.

Also, the following changes were recommended to already registered stents and stent-grafts:

  • Keep endoprostheses for venous lesions under brand name category. Keep Boston Scientific’s Wallstent under the brand name (LPPR code 3120621). Number of characteristics of stents were provided;
  • Keep endoprostheses Viatorr under brand name due to its unique design;
  • Keep stent-graft Viabahn under brand name due its specific characteristics;
  • Keep drug-eluting stents (Zilver PTX, Xience Prime BTK, Promus Element Plus BTK) under brand names with objective to collect complementary data;
  • Move brands Xpert/Xpert PRO et Inperia Advance Carbostent under generic category Self-expanding endoprostheses;
  • Cancel add-on reimbursement for a number of stents due to commercial unavailability of the products.

CNEDiMTS proposed a new version of the section of the LPPR Nomenclature in the annex to its Opinion.

Since the publication of the original Opinion, a minor amendment was published in September 2016 clarifying that objective for maintaining drug-eluting stents under brand names is monitoring the use of devices.

Recently, 11th of July 2017, CNEDiMTS issued the second amendment to its opinion with the following clarifications:

  • Clarification that peripheral drug-eluting stents are not covered within generic stent category and shall be registered by brand names;
  • Interventional environment shall be added to the condition for the use of stents,
  • Dissection of the vessel shall be deleted from an indication for the procedure on upper extremities for LPPR codes 3131694 and code 3171535 (MTRC did not identify these codes in the LPPR List).

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more

07

Mar 2022

On February 08, 2022, the Reimbursement Commission of the Social Security Institution released an updated version of the Healthcare Implementation Communique. The main changes relate to the increase in reimbursement fees of services and medical devices by approximately 35-75%.

Read more